sponsored
PatientsVille.com Logo

PatientsVille

Tavor Medical Research Studies

Up-to-date List of Tavor Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Tavor Medical Research Studies

Rank Status Study
1 Recruiting OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER in Spinal Cord Injured Veterans With Neurogenic Detrusor Overactivity
Condition: Neurogenic Detrusor Overactivity
Interventions: Drug: onabotulinumtoxin A;   Drug: Oxybutynin ER
Outcome Measures: Primary endpoint;   The utility of urinary inflammatory markers as statistically significant predictors of treatment response.
2 Not yet recruiting Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis
Condition: Primary Hyperidrosis
Interventions: Drug: Oxybutynin;   Drug: Placebo
Outcome Measures: Oxybutynin Chloride efficacy;   Perception of improvement;   Evaluate therapeutic safety;   Quality of life;   Time of subject response;   Duration of response;   Evaluation between quality of life and groups
3 Recruiting Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
Conditions: Overactive Detrusor;   Neurogenic Bladder
Intervention: Drug: Oxybutynin
Outcome Measure: Percentage of catheterizations without a leaking accident.
4 Unknown  Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
Condition: Overactive Bladder
Interventions: Drug: Solifenacin;   Drug: Oxybutynin
Outcome Measures: Degree of improvement in overactive bladder symptoms;   To compare the degree of side effects between two study groups
5 Recruiting Oxybutynin and Omega-3 for OAB (Overactive Bladder)
Condition: Overactive Bladder
Intervention: Drug: Omega 3 Fatty Acid
Outcome Measure: Change from baseline in urinary voids per day
6 Recruiting Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome
Condition: Overactive Bladder
Interventions: Drug: Detrusitol 4mg QD and Oxybutynin ER 5mg QD;   Drug: Detrusitol 4mg QD
Outcome Measures: Change from Baseline in the Perception of Bladder Condition (PPBC) at different time points;   Change from Baseline in the Overactive Bladder Symptom Score (OABSS) at different time points;   Change from Baseline in the urinary sensation scale (USS) at different time points;   Change from Baseline in the International Prostate Symptom Score (IPSS) at different time points;   Change from Baseline in the maximum flow rate (Qmax) at different time points;   Change from Baseline in the voided volume at different time points;   Change from Baseline in the postvoid residual volume (PVR) at different time points;   Change from Baseline in the total prostate volume (TPV) at different time points;   Change from Baseline in the transition zone index (TZI) at different time points
7 Unknown  Safety and Efficacy of the Knee-T-nol Anterior Cruciate Ligament (ACL) Prosthesis
Condition: Anterior Cruciate Ligament Rupture
Intervention: Device: Knee-T-Nol
Outcome Measures: Knee stability, as measured by a KT-1000 Arthrometer or Lachman test post procedure;   No treatment emergent SAEs, including Adverse Events of Interest (AEOI), 3 months post procedure.;   Rehabilitation period, defined by Post procedure period [weeks] to successful rehabilitation phase;   Tegner Lysholm scores during the followup period;   Long term safety: no device related SAEs 12 months post procedure.
8 Recruiting A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition
Condition: Urinary Bladder, Neurogenic
Interventions: Drug: Fesoterodine PR 4 mg;   Drug: Fesoterodine PR 8 mg;   Drug: Oxybutynin;   Drug: Fesoterodine PR;   Drug: Fesoterodine BIC 2 mg;   Drug: Fesoterodine BIC 4 mg
Outcome Measures: Maximum cystometric bladder capacity;   Detrusor pressure at maximum bladder capacity;   Presence of involuntary detrusor contractions;   Bladder volume at first involuntary detrusor contraction;   Bladder compliance;   Mean number of micturitions and/or catheterizations/day;   Mean number of incontinence episodes/day;   Mean urgency episodes/day if applicable;   Mean volume voided per micturition or mean volume per catheterization
9 Recruiting Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy
Condition: Urinary Incontinence, Urge
Interventions: Drug: Anticholinergic medications;   Behavioral: Hypnotherapy
Outcome Measures: Urgency Urinary Incontinence episodes recorded on voiding diaries;   Evoked brain activation and resting connectivity on functional MRI;   Urinary urge incontinence cure;   Questionnaire scores;   urinary frequency and pad counts;   Irritable bowel syndrome and bowel symptoms and/or Painful Bladder/Interstitial Cystitis in this population

These studies may lead to new treatments and are adding insight into Tavor etiology and treatment.

A major focus of Tavor research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Tavor